Serrapeptase

A systematic review identified 17 published clinical studies evaluating serrapeptase for a broad range of indications. Bhagat 2013 Most of these studies had poor methodology according to grading by the Scottish Intercollegiate Guidelines Network checklist. Limitations included small sample size, poorly defined enrollment criteria and outcomes, unclear statistical methods, short duration, and failure of some studies to report the dose and duration of therapy. Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. Other conditions evaluated in the low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications. Among the 17 clinical studies identified, 5 were randomized controlled trials published in English and with a low risk of bias and are summarized in the following sections. Al-Khateeb 2008 , Chopra 2009 , Kee 1989 , Mazzone 1990 , Tachibana 1984

A systematic review identified 17 published clinical studies evaluating serrapeptase for a broad range of indications. Bhagat 2013 Most of these studies had poor methodology according to grading by the Scottish Intercollegiate Guidelines Network checklist. Limitations included small sample size, poorly defined enrollment criteria and outcomes, unclear statistical methods, short duration, and failure of some studies to report the dose and duration of therapy. Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. Other conditions evaluated in the low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications. Among the 17 clinical studies identified, 5 were randomized controlled trials published in English and with a low risk of bias and are summarized in the following sections. Al-Khateeb 2008 , Chopra 2009 , Kee 1989 , Mazzone 1990 , Tachibana 1984

Serrapeptase is contraindicated in conditions like Pregnancy, Bleeding disorders.

The symptomatic adverse reactions produced by Serrapeptase are more or less tolerable and if they become severe, they can be treated symptomatically, these include Rare cases of pneumonitis or allergic skin reactions.

Serrapeptase seems to be safe for adults when taken by mouth, short-term. The long-term safety of Serrapeptase is not known.

Drug should not be given to Pregnant Mothers. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

5 to 10 mg (7.5 (7.5)) 3 hourly PO —

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

None well documented.

No storage information is recorded for this medicine yet.